Anonymous
Guest
Anonymous
Guest
Can't believe Lilly is just handing over Amylin and in particular Exenatide to a competitor Bristol Meyers and their partner Astrazeneca. If they are doing so because of Dulaglutide they are making a huge mistake which they will regret for years to come. Looks like Management's arrogance is getting the best of them.